Your browser doesn't support javascript.
loading
Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2H-naphtho[1,2-b][1,4]diazepine-2,4(3H)-diones as P2X4 Receptor Antagonists.
Toti, Kiran S; Verma, Rajkumar; McGonnigle, Michael J; Gamiotea Turro, Daylin; Wen, Zhiwei; Lewicki, Sarah A; Liang, Bruce T; Jacobson, Kenneth A.
Afiliação
  • Toti KS; National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-0810, United States.
  • Verma R; Department of Neuroscience, UConn School of Medicine, Farmington, Connecticut 06032, United States.
  • McGonnigle MJ; Department of Neuroscience, UConn School of Medicine, Farmington, Connecticut 06032, United States.
  • Gamiotea Turro D; Department of Neuroscience, UConn School of Medicine, Farmington, Connecticut 06032, United States.
  • Wen Z; National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-0810, United States.
  • Lewicki SA; National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-0810, United States.
  • Liang BT; Calhoun Cardiology Center, UConn School of Medicine, Farmington, Connecticut 06032, United States.
  • Jacobson KA; National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892-0810, United States.
J Med Chem ; 65(20): 13967-13987, 2022 10 27.
Article em En | MEDLINE | ID: mdl-36150180
ABSTRACT
We analyzed the P2X4 receptor structure-activity relationship of a known antagonist 5, a 1,5-dihydro-2H-naphtho[1,2-b][1,4]diazepine-2,4(3H)-dione. Following extensive modification of the reported synthetic route, 4-pyridyl 21u (MRS4719) and 6-methyl 22c (MRS4596) analogues were most potent at human (h) P2X4R (IC50 0.503 and 1.38 µM, respectively, and selective versus hP2X1R, hP2X2/3R, hP2X3R). Thus, the naphthalene 6-, but not 7-position was amenable to substitution, and an N-phenyl ring aza-scan identified 21u with 3-fold higher activity than 5. Compounds 21u and 22c showed neuroprotective and learning- and memory-enhancing activities in a mouse middle cerebral artery occlusion (MCAO) model of ischemic stroke, with potency of 21u > 22c. 21u dose-dependently reduced infarct volume and reduced brain atrophy at 3 and 35 days post-stroke, respectively. Relevant to clinical implication, 21u also reduced ATP-induced [Ca2+]i influx in primary human monocyte-derived macrophages. This study indicates the translational potential of P2X4R antagonists for treating ischemic stroke, including in aging populations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / AVC Isquêmico Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Neuroprotetores / AVC Isquêmico Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article